Published in Proc Natl Acad Sci U S A on April 11, 1995
A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J (1996) 5.33
An essential role for Prox1 in the induction of the lymphatic endothelial cell phenotype. EMBO J (2002) 5.07
Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium. Am J Pathol (1999) 5.02
Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J (2001) 4.70
Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. Am J Pathol (2002) 4.66
Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci U S A (1998) 4.48
Proteolytic processing regulates receptor specificity and activity of VEGF-C. EMBO J (1997) 4.07
Lymphatic endothelial reprogramming of vascular endothelial cells by the Prox-1 homeobox transcription factor. EMBO J (2002) 3.99
Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3. EMBO J (2001) 3.88
Isolation and characterization of dermal lymphatic and blood endothelial cells reveal stable and functionally specialized cell lineages. J Exp Med (2001) 3.74
Vascular endothelial growth factor C induces angiogenesis in vivo. Proc Natl Acad Sci U S A (1998) 3.72
Regulation of blood and lymphatic vascular separation by signaling proteins SLP-76 and Syk. Science (2003) 3.60
Regulation of Notch1 and Dll4 by vascular endothelial growth factor in arterial endothelial cells: implications for modulating arteriogenesis and angiogenesis. Mol Cell Biol (2003) 3.51
Identification of vascular lineage-specific genes by transcriptional profiling of isolated blood vascular and lymphatic endothelial cells. Am J Pathol (2003) 3.35
VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. Am J Pathol (1999) 3.09
Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. EMBO J (2001) 3.00
Concurrent induction of lymphangiogenesis, angiogenesis, and macrophage recruitment by vascular endothelial growth factor-C in melanoma. Am J Pathol (2001) 2.89
A model for gene therapy of human hereditary lymphedema. Proc Natl Acad Sci U S A (2001) 2.88
Vascular endothelial growth factor-related protein: a ligand and specific activator of the tyrosine kinase receptor Flt4. Proc Natl Acad Sci U S A (1996) 2.77
Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc Natl Acad Sci U S A (1996) 2.71
Molecular characterization of lymphatic endothelial cells. Proc Natl Acad Sci U S A (2002) 2.68
Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth. Nat Med (2009) 2.39
Axon guidance molecules in vascular patterning. Cold Spring Harb Perspect Biol (2010) 2.37
Blockade of vascular endothelial growth factor receptor-3 signaling inhibits fibroblast growth factor-2-induced lymphangiogenesis in mouse cornea. Proc Natl Acad Sci U S A (2002) 2.30
Lymphatic vascular morphogenesis in development, physiology, and disease. J Cell Biol (2011) 2.29
Platelets, petechiae, and preservation of the vascular wall. N Engl J Med (2008) 2.25
Vascular endothelial growth factor receptor-3 in lymphangiogenesis in wound healing. Am J Pathol (2000) 2.24
Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features. Am J Pathol (1999) 2.11
VEGFR-3 controls tip to stalk conversion at vessel fusion sites by reinforcing Notch signalling. Nat Cell Biol (2011) 2.09
Signal transduction by vascular endothelial growth factor receptors. Cold Spring Harb Perspect Med (2012) 1.99
Dose-dependent response of FGF-2 for lymphangiogenesis. Proc Natl Acad Sci U S A (2004) 1.98
Vascular endothelial growth factor-C expression in human prostatic carcinoma and its relationship to lymph node metastasis. Br J Cancer (1999) 1.87
VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours. Br J Cancer (1999) 1.86
Congenital hereditary lymphedema caused by a mutation that inactivates VEGFR3 tyrosine kinase. Am J Hum Genet (2000) 1.86
VEGF-C gene therapy augments postnatal lymphangiogenesis and ameliorates secondary lymphedema. J Clin Invest (2003) 1.84
Nonvascular VEGF receptor 3 expression by corneal epithelium maintains avascularity and vision. Proc Natl Acad Sci U S A (2006) 1.81
The beta-chemokine receptor D6 is expressed by lymphatic endothelium and a subset of vascular tumors. Am J Pathol (2001) 1.80
The lymphatic system in health and disease. Lymphat Res Biol (2008) 1.78
Tumour vascularization: sprouting angiogenesis and beyond. Cancer Metastasis Rev (2007) 1.76
Vascular bed-specific expression of an endothelial cell gene is programmed by the tissue microenvironment. J Cell Biol (1997) 1.74
Prognostic value of lymphangiogenesis and lymphovascular invasion in invasive breast cancer. Ann Surg (2004) 1.72
Stimulation of lymphangiogenesis via VEGFR-3 inhibits chronic skin inflammation. J Exp Med (2010) 1.69
B lymphocyte-specific c-Myc expression stimulates early and functional expansion of the vasculature and lymphatics during lymphomagenesis. Am J Pathol (2003) 1.68
Vascular endothelial growth factor-C (VEGF-C) expression in human colorectal cancer tissues. Br J Cancer (2000) 1.67
Expression of the vascular endothelial growth factor C receptor VEGFR-3 in lymphatic endothelium of the skin and in vascular tumors. Am J Pathol (1998) 1.66
The role of VEGF receptors in angiogenesis; complex partnerships. Cell Mol Life Sci (2006) 1.63
An important role of lymphatic vessel activation in limiting acute inflammation. Blood (2011) 1.62
Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors. Am J Pathol (1998) 1.61
Vascular endothelial growth factor-C (VEGF-C/VEGF-2) promotes angiogenesis in the setting of tissue ischemia. Am J Pathol (1998) 1.61
Notch alters VEGF responsiveness in human and murine endothelial cells by direct regulation of VEGFR-3 expression. J Clin Invest (2007) 1.60
A novel multistep mechanism for initial lymphangiogenesis in mouse embryos based on ultramicroscopy. EMBO J (2013) 1.58
Doxycycline reduces plasma VEGF-C/sVEGFR-3 and improves pathology in lymphatic filariasis. PLoS Pathog (2006) 1.57
Soluble vascular endothelial growth factor receptor 3 is essential for corneal alymphaticity. Blood (2013) 1.56
First international consensus on the methodology of lymphangiogenesis quantification in solid human tumours. Br J Cancer (2006) 1.53
Ocular lymphatics: state-of-the-art review. Lymphology (2009) 1.52
The secretory proprotein convertases furin, PC5, and PC7 activate VEGF-C to induce tumorigenesis. J Clin Invest (2003) 1.51
Inflammation induces lymphangiogenesis through up-regulation of VEGFR-3 mediated by NF-kappaB and Prox1. Blood (2009) 1.50
Lymphangiogenesis and lymphatic metastasis in breast cancer. Pathophysiology (2009) 1.48
Vascular endothelial growth factor D is dispensable for development of the lymphatic system. Mol Cell Biol (2005) 1.47
Deletion of vascular endothelial growth factor C (VEGF-C) and VEGF-D is not equivalent to VEGF receptor 3 deletion in mouse embryos. Mol Cell Biol (2008) 1.47
Lymphangiogenesis and cancer metastasis. J Cell Mol Med (2009) 1.47
Mechanisms of lymphatic metastasis. J Clin Invest (2014) 1.46
Lymphatic function is required prenatally for lung inflation at birth. J Exp Med (2014) 1.44
The VEGF family in cancer and antibody-based strategies for their inhibition. MAbs (2011) 1.41
Lymphangiogenic growth factor responsiveness is modulated by postnatal lymphatic vessel maturation. Am J Pathol (2006) 1.39
Transgenic induction of vascular endothelial growth factor-C is strongly angiogenic in mouse embryos but leads to persistent lymphatic hyperplasia in adult tissues. Am J Pathol (2008) 1.38
VEGF-A, VEGF-C, and VEGF-D in colorectal cancer progression. Neoplasia (2001) 1.37
Pathogenesis of lymphangiomas. Virchows Arch (2008) 1.35
Microarray analysis of Foxa2 mutant mouse embryos reveals novel gene expression and inductive roles for the gastrula organizer and its derivatives. BMC Genomics (2008) 1.35
Endothelial cell plasticity: how to become and remain a lymphatic endothelial cell. Development (2010) 1.34
Spreds are essential for embryonic lymphangiogenesis by regulating vascular endothelial growth factor receptor 3 signaling. Mol Cell Biol (2007) 1.34
Novel aspects of corneal angiogenic and lymphangiogenic privilege. Prog Retin Eye Res (2010) 1.33
Role of vascular permeability factor/vascular endothelial growth factor in eye disease. Br J Ophthalmol (1997) 1.29
Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen prolongs the life span of primary human umbilical vein endothelial cells. J Virol (2003) 1.28
The formation of lymphatic vessels and its importance in the setting of malignancy. J Exp Med (2002) 1.28
Novel expression of vascular endothelial growth factor receptor (VEGFR)-3 and VEGF-C on corneal dendritic cells. Am J Pathol (2003) 1.28
Lymphangiogenic factors, mechanisms, and applications. J Clin Invest (2014) 1.27
Vascular growth factors and receptors in capillary hemangioblastomas and hemangiopericytomas. Am J Pathol (1996) 1.25
Biomarkers of traumatic injury are transported from brain to blood via the glymphatic system. J Neurosci (2015) 1.25
Lack of lymphangiogenesis during breast carcinogenesis. J Clin Pathol (2004) 1.25
Contribution of macrophages to angiogenesis induced by vascular endothelial growth factor receptor-3-specific ligands. Am J Pathol (2009) 1.23
LYVE-1 immunohistochemical assessment of lymphangiogenesis in endometrial and lung cancer. J Clin Pathol (2005) 1.22
Lymphatics at the crossroads of angiogenesis and lymphangiogenesis. J Anat (2004) 1.22
Ontogeny of stromal organizer cells during lymph node development. J Immunol (2010) 1.20
Net-targeted mutant mice develop a vascular phenotype and up-regulate egr-1. EMBO J (2001) 1.20
Filariasis and lymphoedema. Parasite Immunol (2009) 1.20
Blockade of VEGFR3-signalling specifically inhibits lymphangiogenesis in inflammatory corneal neovascularisation. Graefes Arch Clin Exp Ophthalmol (2007) 1.20
VEGF-C-dependent stimulation of lymphatic function ameliorates experimental inflammatory bowel disease. J Clin Invest (2014) 1.20
In vivo imaging of lymphatic vessels in development, wound healing, inflammation, and tumor metastasis. Proc Natl Acad Sci U S A (2012) 1.19
Vascular endothelial growth factor-D is an independent prognostic factor in epithelial ovarian carcinoma. Br J Cancer (2003) 1.18
Lasting controversy on ranibizumab and bevacizumab. Theranostics (2011) 1.15
Emilin1 deficiency causes structural and functional defects of lymphatic vasculature. Mol Cell Biol (2008) 1.14
Specification of arterial, venous, and lymphatic endothelial cells during embryonic development. Histol Histopathol (2010) 1.12
Spontaneous corneal hem- and lymphangiogenesis in mice with destrin-mutation depend on VEGFR3 signaling. Am J Pathol (2005) 1.09
The sialomucin CD34 is a marker of lymphatic endothelial cells in human tumors. Am J Pathol (2006) 1.09
Podoplanin-expressing cells derived from bone marrow play a crucial role in postnatal lymphatic neovascularization. Circulation (2010) 1.07
Macrophage-mediated lymphangiogenesis: the emerging role of macrophages as lymphatic endothelial progenitors. Cancers (Basel) (2012) 1.06
The cutaneous vascular system in chronic skin inflammation. J Investig Dermatol Symp Proc (2011) 1.06
Angiogenic factors. Science (1987) 15.22
Angiogenesis. J Biol Chem (1992) 11.29
The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science (1992) 7.49
High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell (1993) 7.14
Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol (1992) 6.13
The role of angiogenesis in tumor growth. Semin Cancer Biol (1992) 5.33
Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun (1992) 5.31
Nucleotide sequence of a full-length cDNA for mouse cytoskeletal beta-actin mRNA. Nucleic Acids Res (1986) 4.36
Tie-1 and tie-2 define another class of putative receptor tyrosine kinase genes expressed in early embryonic vascular system. Proc Natl Acad Sci U S A (1993) 3.37
Regulators of angiogenesis. Annu Rev Physiol (1991) 3.27
Endothelial proliferation in tumours and normal tissues: continuous labelling studies. Br J Cancer (1984) 2.55
A novel endothelial cell surface receptor tyrosine kinase with extracellular epidermal growth factor homology domains. Mol Cell Biol (1992) 2.34
Nucleotide sequence of pre-pro-von Willebrand factor cDNA. Nucleic Acids Res (1986) 2.32
Unique expression pattern of the FGF receptor 3 gene during mouse organogenesis. Dev Biol (1993) 2.28
FLT4 receptor tyrosine kinase contains seven immunoglobulin-like loops and is expressed in multiple human tissues and cell lines. Cancer Res (1992) 1.99
Vasculogenesis in the early quail blastodisc as studied with a monoclonal antibody recognizing endothelial cells. Development (1987) 1.89
Embryonic vascular development: immunohistochemical identification of the origin and subsequent morphogenesis of the major vessel primordia in quail embryos. Development (1988) 1.88
Embryonic origins and assembly of blood vessels. Am Rev Respir Dis (1989) 1.77
Induction of vasculogenesis and hematopoiesis in vitro. Development (1992) 1.74
Signalling properties of FLT4, a proteolytically processed receptor tyrosine kinase related to two VEGF receptors. Oncogene (1994) 1.73
Enhanced expression of the tie receptor tyrosine kinase in endothelial cells during neovascularization. Blood (1992) 1.65
The related FLT4, FLT1, and KDR receptor tyrosine kinases show distinct expression patterns in human fetal endothelial cells. J Exp Med (1993) 1.62
Two human FLT4 receptor tyrosine kinase isoforms with distinct carboxy terminal tails are produced by alternative processing of primary transcripts. Oncogene (1993) 1.61
The mouse tie receptor tyrosine kinase gene: expression during embryonic angiogenesis. Oncogene (1994) 1.45
Congenital malformations of the cervicothoracic lymphatic system: embryology and pathogenesis. Radiographics (1992) 1.40
Molecular cloning of murine FLT and FLT4. Oncogene (1993) 1.37
Effect of thrombin on the production of plasminogen activators and PA inhibitor-1 by human foreskin microvascular endothelial cells. Thromb Haemost (1987) 1.25
Production of plasminogen activators and inhibitor by serially propagated endothelial cells from adult human blood vessels. Arteriosclerosis (1987) 1.16
Vasculogenesis in the chick embryo. An ultrastructural study. Am J Anat (1971) 1.07
The development of the lymphatic system in man. Adv Anat Embryol Cell Biol (1975) 1.03
16-kilodalton heparin binding (fibroblast) growth factor type one appears in a stable 40-kilodalton complex after receptor-dependent internalization. J Biol Chem (1991) 0.99
Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. Nature (1983) 8.18
Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med (2001) 7.78
Homogeneously staining chromosomal regions contain amplified copies of an abundantly expressed cellular oncogene (c-myc) in malignant neuroendocrine cells from a human colon carcinoma. Proc Natl Acad Sci U S A (1983) 7.01
Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science (1997) 6.37
A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J (1996) 5.33
Cardiovascular failure in mouse embryos deficient in VEGF receptor-3. Science (1998) 5.07
Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium. Am J Pathol (1999) 5.02
Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J (2001) 4.70
Distribution of human herpesvirus-8 latently infected cells in Kaposi's sarcoma, multicentric Castleman's disease, and primary effusion lymphoma. Proc Natl Acad Sci U S A (1999) 4.52
Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Nat Med (2001) 4.50
Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci U S A (1998) 4.48
Clinical applications of angiogenic growth factors and their inhibitors. Nat Med (1999) 4.26
Proteolytic processing regulates receptor specificity and activity of VEGF-C. EMBO J (1997) 4.07
Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3. EMBO J (2001) 3.88
Identification of nuclear proteins encoded by viral and cellular myc oncogenes. Nature (1984) 3.86
PDGF-C is a new protease-activated ligand for the PDGF alpha-receptor. Nat Cell Biol (2000) 3.81
Vascular endothelial growth factor C induces angiogenesis in vivo. Proc Natl Acad Sci U S A (1998) 3.72
Missense mutations interfere with VEGFR-3 signalling in primary lymphoedema. Nat Genet (2000) 3.66
A cellular oncogene (c-Ki-ras) is amplified, overexpressed, and located within karyotypic abnormalities in mouse adrenocortical tumour cells. Nature (1983) 3.56
Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer Res (2001) 3.38
FGFR-4, a novel acidic fibroblast growth factor receptor with a distinct expression pattern. EMBO J (1991) 3.19
The receptor tyrosine kinase TIE is required for integrity and survival of vascular endothelial cells. EMBO J (1995) 3.16
VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. Am J Pathol (1999) 3.09
Endothelial receptor tyrosine kinases involved in angiogenesis. J Cell Biol (1995) 3.06
Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. EMBO J (2001) 3.00
Vascular abnormalities and deregulation of VEGF in Lkb1-deficient mice. Science (2001) 2.99
Concurrent induction of lymphangiogenesis, angiogenesis, and macrophage recruitment by vascular endothelial growth factor-C in melanoma. Am J Pathol (2001) 2.89
A model for gene therapy of human hereditary lymphedema. Proc Natl Acad Sci U S A (2001) 2.88
Vascular endothelial growth factor is induced in response to transforming growth factor-beta in fibroblastic and epithelial cells. J Biol Chem (1994) 2.87
Vascularization of the mouse embryo: a study of flk-1, tek, tie, and vascular endothelial growth factor expression during development. Dev Dyn (1995) 2.83
VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development. Development (1996) 2.82
Induction of a basement membrane glycoprotein in embryonic kidney: possible role of laminin in morphogenesis. Proc Natl Acad Sci U S A (1980) 2.74
Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc Natl Acad Sci U S A (1996) 2.71
PDGF-D is a specific, protease-activated ligand for the PDGF beta-receptor. Nat Cell Biol (2001) 2.70
Repression of cyclin D1: a novel function of MYC. Mol Cell Biol (1994) 2.67
Nucleotide sequence to the v-myc oncogene of avian retrovirus MC29. Proc Natl Acad Sci U S A (1983) 2.66
Absence of functional lymphatics within a murine sarcoma: a molecular and functional evaluation. Cancer Res (2000) 2.64
Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res (2000) 2.63
Lymphatic endothelium and Kaposi's sarcoma spindle cells detected by antibodies against the vascular endothelial growth factor receptor-3. Cancer Res (1998) 2.60
Oncogene amplification in tumor cells. Adv Cancer Res (1986) 2.44
Fibronectin is produced by human macrophages. J Exp Med (1980) 2.44
VEGF and VEGF-C: specific induction of angiogenesis and lymphangiogenesis in the differentiated avian chorioallantoic membrane. Dev Biol (1997) 2.43
Localization of putative stem cells in dental epithelium and their association with Notch and FGF signaling. J Cell Biol (1999) 2.39
A novel endothelial cell surface receptor tyrosine kinase with extracellular epidermal growth factor homology domains. Mol Cell Biol (1992) 2.34
Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. Proc Natl Acad Sci U S A (1998) 2.32
Proinflammatory cytokines regulate expression of the lymphatic endothelial mitogen vascular endothelial growth factor-C. J Biol Chem (1998) 2.28
Activation of RhoA by thrombin in endothelial hyperpermeability: role of Rho kinase and protein tyrosine kinases. Circ Res (2000) 2.26
VEGFs, receptors and angiogenesis. Semin Cancer Biol (1999) 2.25
Vascular endothelial growth factor receptor-3 in lymphangiogenesis in wound healing. Am J Pathol (2000) 2.24
Interaction of endostatin with integrins implicated in angiogenesis. Proc Natl Acad Sci U S A (2001) 2.19
Isolation of the pericellular matrix of human fibroblast cultures. J Cell Biol (1979) 2.19
The human p50csk tyrosine kinase phosphorylates p56lck at Tyr-505 and down regulates its catalytic activity. EMBO J (1992) 2.16
Cells derived from omental fat tissue and used for seeding vascular prostheses are not endothelial in origin. A study on the origin of epitheloid cells derived from omentum. J Vasc Surg (1991) 2.06
VEGF-C and VEGF-D expression in neuroendocrine cells and their receptor, VEGFR-3, in fenestrated blood vessels in human tissues. FASEB J (2000) 2.06
Tie receptors: new modulators of angiogenic and lymphangiogenic responses. Nat Rev Mol Cell Biol (2001) 2.05
FLT4 receptor tyrosine kinase contains seven immunoglobulin-like loops and is expressed in multiple human tissues and cell lines. Cancer Res (1992) 1.99
A recombinant mutant vascular endothelial growth factor-C that has lost vascular endothelial growth factor receptor-2 binding, activation, and vascular permeability activities. J Biol Chem (1998) 1.98
Lack of lymphatic vascular specificity of vascular endothelial growth factor receptor 3 in 185 vascular tumors. Cancer (1999) 1.97
Biological action of angiopoietin-2 in a fibrin matrix model of angiogenesis is associated with activation of Tie2. Cardiovasc Res (2001) 1.95
A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J (1996) 1.95
Biosynthesis of vascular endothelial growth factor-D involves proteolytic processing which generates non-covalent homodimers. J Biol Chem (1999) 1.94
Biosynthesis of two subunits of type IV procollagen and of other basement membrane proteins by a human tumor cell line. Eur J Biochem (1980) 1.90
Vascular endothelial growth factor-C expression in human prostatic carcinoma and its relationship to lymph node metastasis. Br J Cancer (1999) 1.87
Involvement of SOX proteins in lens-specific activation of crystallin genes. EMBO J (1995) 1.86
Congenital hereditary lymphedema caused by a mutation that inactivates VEGFR3 tyrosine kinase. Am J Hum Genet (2000) 1.86
Comparison of VEGF, VEGF-B, VEGF-C and Ang-1 mRNA regulation by serum, growth factors, oncoproteins and hypoxia. Oncogene (1997) 1.85
Two alternative mRNAs coding for the angiogenic factor, placenta growth factor (PlGF), are transcribed from a single gene of chromosome 14. Oncogene (1993) 1.83
Regulation of matrix metalloproteinase expression in human vein and microvascular endothelial cells. Effects of tumour necrosis factor alpha, interleukin 1 and phorbol ester. Biochem J (1993) 1.83
Matrix metalloproteinase-8 is expressed in rheumatoid synovial fibroblasts and endothelial cells. Regulation by tumor necrosis factor-alpha and doxycycline. J Biol Chem (1997) 1.82
Peripheral blood platelets express VEGF-C and VEGF which are released during platelet activation. Thromb Haemost (1998) 1.80
Structure, expression and receptor-binding properties of novel vascular endothelial growth factors. Curr Top Microbiol Immunol (1999) 1.79
Involvement of vascular endothelial growth factor receptor-3 in maintenance of integrity of endothelial cell lining during tumor angiogenesis. Blood (2000) 1.76
Transient and prolonged increase in endothelial permeability induced by histamine and thrombin: role of protein kinases, calcium, and RhoA. Circ Res (1998) 1.74
Signalling properties of FLT4, a proteolytically processed receptor tyrosine kinase related to two VEGF receptors. Oncogene (1994) 1.73
Adenoviral expression of vascular endothelial growth factor-C induces lymphangiogenesis in the skin. Circ Res (2001) 1.71
Enhanced jun gene expression is an early genomic response to transforming growth factor beta stimulation. Mol Cell Biol (1989) 1.70
Alternative forms of Max as enhancers or suppressors of Myc-ras cotransformation. Science (1992) 1.70
Plasma concentration of C-reactive protein is increased in type I diabetic patients without clinical macroangiopathy and correlates with markers of endothelial dysfunction: evidence for chronic inflammation. Diabetologia (1999) 1.67
Role of RhoA and Rho kinase in lysophosphatidic acid-induced endothelial barrier dysfunction. Arterioscler Thromb Vasc Biol (2000) 1.66
Expression of the vascular endothelial growth factor C receptor VEGFR-3 in lymphatic endothelium of the skin and in vascular tumors. Am J Pathol (1998) 1.66
Enhanced expression of the tie receptor tyrosine kinase in endothelial cells during neovascularization. Blood (1992) 1.65
Expression of vascular endothelial growth factor receptor-3 and podoplanin suggests a lymphatic endothelial cell origin of Kaposi's sarcoma tumor cells. Lab Invest (1999) 1.62
The related FLT4, FLT1, and KDR receptor tyrosine kinases show distinct expression patterns in human fetal endothelial cells. J Exp Med (1993) 1.62
Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors. Am J Pathol (1998) 1.61
Refined assignment of the infantile neuronal ceroid lipofuscinosis (INCL, CLN1) locus at 1p32: incorporation of linkage disequilibrium in multipoint analysis. Genomics (1993) 1.61
Subcellular location of an abundant substrate (p36) for tyrosine-specific protein kinases. Mol Cell Biol (1983) 1.61
Two human FLT4 receptor tyrosine kinase isoforms with distinct carboxy terminal tails are produced by alternative processing of primary transcripts. Oncogene (1993) 1.61
Differential binding of vascular endothelial growth factor B splice and proteolytic isoforms to neuropilin-1. J Biol Chem (1999) 1.61
Identification of Tek/Tie2 binding partners. Binding to a multifunctional docking site mediates cell survival and migration. J Biol Chem (1999) 1.60
Expression of endothelial cell-specific receptor tyrosine kinases and growth factors in human brain tumors. Am J Pathol (1995) 1.60